JP2025511401A5 - - Google Patents

Info

Publication number
JP2025511401A5
JP2025511401A5 JP2024559034A JP2024559034A JP2025511401A5 JP 2025511401 A5 JP2025511401 A5 JP 2025511401A5 JP 2024559034 A JP2024559034 A JP 2024559034A JP 2024559034 A JP2024559034 A JP 2024559034A JP 2025511401 A5 JP2025511401 A5 JP 2025511401A5
Authority
JP
Japan
Application number
JP2024559034A
Other languages
Japanese (ja)
Other versions
JPWO2023194528A5 (https=
JP2025511401A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/EP2023/059126 external-priority patent/WO2023194528A1/en
Publication of JP2025511401A publication Critical patent/JP2025511401A/ja
Publication of JPWO2023194528A5 publication Critical patent/JPWO2023194528A5/ja
Publication of JP2025511401A5 publication Critical patent/JP2025511401A5/ja
Pending legal-status Critical Current

Links

JP2024559034A 2022-04-07 2023-04-06 癌を治療するための併用療法 Pending JP2025511401A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US202263362612P 2022-04-07 2022-04-07
US63/362,612 2022-04-07
PCT/EP2023/059126 WO2023194528A1 (en) 2022-04-07 2023-04-06 Combination therapy for treating cancer

Publications (3)

Publication Number Publication Date
JP2025511401A JP2025511401A (ja) 2025-04-15
JPWO2023194528A5 JPWO2023194528A5 (https=) 2026-04-10
JP2025511401A5 true JP2025511401A5 (https=) 2026-04-10

Family

ID=86185292

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2024559034A Pending JP2025511401A (ja) 2022-04-07 2023-04-06 癌を治療するための併用療法

Country Status (11)

Country Link
US (1) US20250235448A1 (https=)
EP (1) EP4504180A1 (https=)
JP (1) JP2025511401A (https=)
KR (1) KR20240170956A (https=)
CN (1) CN118973572A (https=)
AU (1) AU2023248685A1 (https=)
CA (1) CA3254948A1 (https=)
IL (1) IL316016A (https=)
MX (1) MX2024012368A (https=)
TW (1) TW202404593A (https=)
WO (1) WO2023194528A1 (https=)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2026021478A1 (zh) * 2024-07-23 2026-01-29 江苏恒瑞医药股份有限公司 Ar降解剂与parp1抑制剂联合用于治疗前列腺癌的方法

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0705903B2 (en) 1994-08-12 2009-08-12 The University of Utah Research Foundation Mutations in the 17q-linked breast and ovarian cancer susceptibility gene
DK0699754T3 (da) 1994-08-12 2001-02-26 Myriad Genetics Inc Fremgangsmåde til diagnosticering af prædisposition for bryst- og ovariecancer
AR078793A1 (es) 2009-10-27 2011-12-07 Orion Corp Derivados de carboxamidas no esteroidales y acil hidrazona moduladores de receptores androgenicos de tejido selectivo (sarm), composiciones farmaceuticas que los contienen y uso de los mismos en el tratamiento del cancer de prostata entre otros
MX2022000711A (es) 2019-07-19 2022-02-23 Astrazeneca Ab Inhibidores de parp1.
TW202228693A (zh) * 2020-10-08 2022-08-01 瑞典商阿斯特捷利康公司 用於治療癌症之組合療法

Similar Documents

Publication Publication Date Title
JP2025511401A5 (https=)
JP2025511403A5 (https=)
CL2025003837A1 (es) Anticuerpo monoclonal o fragmento unión a antígeno del mismo que se une específicamente a axl
BR102023005164A2 (https=)
BR102022026909A2 (https=)
BY13175U (https=)
CN307044327S (https=)
CN307048512S (https=)
CN307048406S (https=)
CN307048341S (https=)
CN307048222S (https=)
CN307048026S (https=)
CN307047954S (https=)
CN307047663S (https=)
CN307047598S (https=)
CN307046320S (https=)
CN307045648S (https=)
CN307045523S (https=)
BY13168U (https=)
CN307044372S (https=)
BY13169U (https=)
CN307044289S (https=)
BY23963C1 (https=)
BY13176U (https=)
BY13165U (https=)